Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Capital Expenditures: 2019-2025

Historic Capital Expenditures for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to $5.0 million.

  • Beam Therapeutics' Capital Expenditures rose 217.76% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 million, marking a year-over-year increase of 48.27%. This contributed to the annual value of $8.9 million for FY2024, which is 73.48% down from last year.
  • Latest data reveals that Beam Therapeutics reported Capital Expenditures of $5.0 million as of Q3 2025, which was up 59.79% from $3.1 million recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Capital Expenditures peaked at $16.2 million during Q2 2021, and registered a low of $1.6 million during Q3 2024.
  • In the last 3 years, Beam Therapeutics' Capital Expenditures had a median value of $3.1 million in 2025 and averaged $4.9 million.
  • As far as peak fluctuations go, Beam Therapeutics' Capital Expenditures spiked by 583.73% in 2021, and later slumped by 82.98% in 2024.
  • Beam Therapeutics' Capital Expenditures (Quarterly) stood at $13.4 million in 2021, then crashed by 38.21% to $8.3 million in 2022, then tumbled by 56.55% to $3.6 million in 2023, then declined by 17.25% to $3.0 million in 2024, then skyrocketed by 217.76% to $5.0 million in 2025.
  • Its last three reported values are $5.0 million in Q3 2025, $3.1 million for Q2 2025, and $3.1 million during Q1 2025.